Skip to main content
SpringerLink
Log in

Malignancy of the Prostate Gland

  • Chapter
Lower Genitourinary Radiology

  • 231 Accesses

Abstract

Cancer of the prostate has been propelled into the limelight of the American public for many reasons. It the most common internal cancer in men (followed only by lung cancer) and the second most common cancer death (second only to lung cancer). There are many reasons for the apparent increase in the incidence of prostate cancer. The population expansion coupled by increasing life expectancy and dramatic improvement in the technologies to diagnose prostate cancer made this disease a target not only by the scientific community but by the lay public as well. The objective of this chapter is to review the basic information and present the most recent advances regarding prostatic carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Silverberg E, Boring CC, Squires TS. Cancer statistics, 1990. CA 1990; 210: 9

    Google Scholar 

  2. Scardino PT. What is the rationale for treating localized prostate cancer? AUA Today 1995; 8: 10

    Google Scholar 

  3. Gilliland FD, Becker TM, Key CR, et al. Contrasting trends of prostate cancer incidence and mortality in New Mexico’s Hispanics, non-Hispanic Whites, American Indians and Blacks. Cancer 1994; 73: 2192–2199

    Article  PubMed  CAS  Google Scholar 

  4. Taylor JD, Holmes TM, Swanson GM. Descriptive epidemiology of prostate cancer in metropolitan Detroit. Cancer 1994; 73: 1704–1707

    Article  PubMed  CAS  Google Scholar 

  5. Devesa SS, Silvermanø DT, Young JL Jr, et al. Cancer incidence and mortality trends among Whites in the United States, 1947-84. J Natl Cancer Inst 1987; 79: 701–770.

    PubMed  CAS  Google Scholar 

  6. Ernster VL, Winkelstein W Jr, Selvin S, et al. Race, socioeconomic status, and prostate cancer. Cancer Treat Rep 1977; 61: 187–191

    PubMed  CAS  Google Scholar 

  7. Hirst AE, Bergman AT. Carcinoma of the prostate in men 80 or more years old. Cancer 1954; 7: 136–141

    Article  PubMed  Google Scholar 

  8. Aprikian AG, Zhang ZF, Fair WR. Prostate adenocarcinoma in men younger than 50 years: a retrospective review of 151 patients. Cancer 1994; 74: 1768–1777

    Article  PubMed  CAS  Google Scholar 

  9. Steinberg GD, Carter BS, Beaty TH, et al. Family history and the risk of prostate cancer. Prostate 1990; 17: 337

    Article  PubMed  CAS  Google Scholar 

  10. Aprikian AG, Bazinet M, Plante M, et al. Family history and the risk of prostatic carcinoma in a high risk group of urological patients. J Urol 1995; 154: 404–406

    Article  PubMed  CAS  Google Scholar 

  11. Moore RA. Endocrinology of Neoplastic Disease. New York, Oxford University Press, 1947

    Google Scholar 

  12. Kolonel LN, Hankin JH, Nomura AMY, et al. Studies of nutrients and their relationship to cancer in the multiethnic population of Hawaii. Adv Exp Med Biol 1986; 206: 35–43

    PubMed  CAS  Google Scholar 

  13. Carroll KK, Kohr HT. Dietary fat in relation to tumorigenesis. Prog Biochem Pharmacol 1975; 10: 308–353

    PubMed  CAS  Google Scholar 

  14. McNeal JE. Normal histology of the prostate. Am J Surg Pathol 1988; 12: 619–633

    Article  PubMed  CAS  Google Scholar 

  15. Gleason DF. Histologic grading and staging of prostate of prostatic carcinoma. In: Tannenbaum M (ed). Urologic Pathology: the Prostate. Philadelphia, Lea & Febiger, 1977: 171–179

    Google Scholar 

  16. Winkler HZ, Rainwater LM, Myers RP, et al. Stage D1 prostatic adenocarcinoma: significance of nuclear DNA ploidy patterns studied by flow cytometry. Mayo Clin Proc 1988; 63: 103–112

    PubMed  CAS  Google Scholar 

  17. Stephenson RA, James BC, Gay H, et al. Flow cytometry of prostate cancer: relationship of DNA content to survival. Urol Radiol 1987; 47: 2504–2509

    CAS  Google Scholar 

  18. Carmichael MJ, Veltri RW, Partin AW, et al. Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease. J Urol 1995; 153: 1015–1019

    Article  PubMed  CAS  Google Scholar 

  19. Monda JM, Barry MJ, Oesterling JE. Prostate specific antigen cannot distinguish stage T1a (A1) prostate cancer from benign prostatic hyperplasia. J Urol 1994; 151: 1291–1295

    PubMed  CAS  Google Scholar 

  20. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151: 1283–1290

    PubMed  CAS  Google Scholar 

  21. Cooner WH, Mosley BR, Rutherford CL Jr, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 1990; 143: 1146–1154

    PubMed  CAS  Google Scholar 

  22. Feightner JW. The early detection and treatment of prostate cancer: the perspective of the Canadian Task Force on the periodic health examination. J Urol 1994; 152: 1682–1684

    PubMed  CAS  Google Scholar 

  23. Stamey TA. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. Monogr Urol 1989; 10: 50

    Google Scholar 

  24. Oesterling JE. Using prostate-specific antigen to eliminate unnecessary diagnostic tests: significant worldwide economic implications. Urology 1995; 46: 26–33

    Article  PubMed  CAS  Google Scholar 

  25. Oesterling JE, Jacobsen SJ, Cooner WH. The use of age-specific reference ranges for serum prostate specific antigen in men 60 years old or older. J Urol 1995; 153: 1160–1163

    Article  PubMed  CAS  Google Scholar 

  26. Bretton PR, Evans WP, Borden JD, et al. The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostatic carcinoma. Cancer 1994; 74: 2991–2995

    Article  PubMed  CAS  Google Scholar 

  27. Cookson MS, Floyd MK, Ball TP Jr, et al. The lack of predictive value of prostate specific antigen density in the detection of prostate cancer in patients with normal rectal examinations and intermediate prostate specific antigen levels. J Urol 1995; 154: 1070–1073

    Article  PubMed  CAS  Google Scholar 

  28. Carter HB, Pearson JE, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215–2220

    Article  PubMed  CAS  Google Scholar 

  29. Catalona WJ, Smith DS, Ratliff TL. Value of measurements of the rate of change on serum PSA levels in prostate cancer screening. J Urol 1993; 149: 300A

    Google Scholar 

  30. Brawer MK. Screening for prostate cancer. Monogr Urol 1994; 15: 1–24

    Google Scholar 

  31. Stamey TA, Yang N, Hay AR, et al. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 3l7: 909–916

    Article  Google Scholar 

  32. Zagars GK, von Eschenbach AC. Prostate specific antigen: an important marker for prostate cancer treated by external beam radiation therapy. Cancer 1993; 72: 538–548

    Article  PubMed  CAS  Google Scholar 

  33. Zietman AL, Coen JJ, Shipley WU, et al. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol 1994; 151: 640–645

    PubMed  CAS  Google Scholar 

  34. Stamey TA, Ferrari MK, Schmid HP. The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients. J Urol 1993; 150: 1856–1859

    PubMed  CAS  Google Scholar 

  35. Ritter MA, Messing EM, Shanahan TG, et al. Prostate specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J Clin Oncol 1992; 10: 1208–1217

    PubMed  CAS  Google Scholar 

  36. Stenman UH, Leinonen J, Alfthan H, et al. A complex between prostate-specific antigen and alpha 1-antichy-motrypsin is the major form of the prostate-specific antigen in serum of patients with prostate cancer: assay of the complex improves clinical sensitivity for cancer. Urol Radiol 1991; 51: 222–226

    CAS  Google Scholar 

  37. Oesterling JE, Jacobsen SJ, Klee GG, et al. Free complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995; 154: 1090–1095

    Article  PubMed  CAS  Google Scholar 

  38. Catalona WJ, Smith DS, Wolfert RL, et al. Increased specificity of PSA screening through measurement of percent free PSA in serum. J Urol 1995; 153: 312A

    Google Scholar 

  39. Hodge KK, McNeal JE, Terris MK, et al. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989; 142: 71–75

    PubMed  CAS  Google Scholar 

  40. Chybowski FM, Larson-Keller JJ, Bergstralh EJ, et al. Predicting radionuclide bone scan findings in patients with newly diagnosed untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 1991; 145: 313–318

    PubMed  CAS  Google Scholar 

  41. Lowe FC, Trauzzi SJ. Prostatic acid phosphatase in 1993: its limited clinical utility. Urol Clin North Am 1993; 20: 589–595

    PubMed  CAS  Google Scholar 

  42. Levran Z, Gonzalez JA, Diokno AC, et al. Are pelvic computed tomography, bone scan and pelvic lymphadenec-tomy necessary in the staging of prostatic cancer? Br J Urol 1995; 75: 778–781

    Article  PubMed  CAS  Google Scholar 

  43. Outwater EK, Peterson RO, Siegelman ES, et al. Prostate carcinoma: assessment of diagnostic criteria for capsular penetration on endorectal coil MR images. Radiology 1994; 193: 333–339

    PubMed  CAS  Google Scholar 

  44. Tempany CM, Zhou X, Zerhouni EA, et al. Staging of prostate cancer: results of radiology diagnostic oncology group comparison of three MR imaging techniques. Radiology 1994; 192: 47–54

    PubMed  CAS  Google Scholar 

  45. Bluestein DL, Bostwick DG, Bergstralh EJ, et al. Eliminating the need for bilateral pelvic lymphadenectomy in selec_ patients with prostate cancer. J Urol 1994; 151: 1315–1320

    PubMed  CAS  Google Scholar 

  46. Partin AW, Pound CR, Clemens JQ, et al. Serum PSA after anatomic radical prostatectomy: the Johns Hopkins experience after 10 years. Urol Clin North Am 1993; 20: 713–725

    PubMed  CAS  Google Scholar 

  47. Middleton RG, Thompson IM, Austenfeld MS, et al. The Management of Localized Prostate Cancer: A Patient’s Guide. American Urological Association, Baltimore, 1995

    Google Scholar 

  48. Adolfsson J, Ronstrom L, Lowhagen T, et al. Deferred treatment of clinically localized low grade prostate cancer: the experience from a prospective series at the Karolinska Hospital. J Urol 1994; 152: 1757–1760

    PubMed  CAS  Google Scholar 

  49. Soloway MS, Sharifi R, Wajsman Z, et al. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J Urol 1995; 154: 424–428

    Article  PubMed  CAS  Google Scholar 

  50. Hanks GE, Hanlon A, Schultheiss T, et al. Early prostate cancer: the national results of radiation treatment from the patterns of care and radiation therapy oncology group studies with prospects for improvement with conformai radiation and adjuvant androgen deprivation. J Urol 1994; 152: 1775–1780

    PubMed  CAS  Google Scholar 

  51. Eisbruch A, Perez CA, Roesler EH, et al. Adjuvant irradiation after prostatectomy for carcinoma of the prostate with positive surgical margins. Cancer 1994; 73: 384–388

    Article  PubMed  CAS  Google Scholar 

  52. Cookson MS, Sarosdy ME Hormonal therapy for metastatic prostate cancer: issues of timing and total androgen ablation. South Med J 1994; 87: l–6

    Article  Google Scholar 

Download references

Authors
  1. Ananias C. Diokno
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jose A. Gonzalez
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Wayne State University School of Medicine, Detroit, MI, 48202, USA

    Syed Zafar H. Jafri M.D. (Clinical Associate Professor, Chief) (Clinical Associate Professor, Chief)

  2. Section of Uroradiology, William Beaumont Hospital, Royal Oak, MI, 48073, USA

    Syed Zafar H. Jafri M.D. (Clinical Associate Professor, Chief) (Clinical Associate Professor, Chief)

  3. University of Michigan Medical School, Ann Arbor, MI, 48109, USA

    Ananias C. Diokno M.D. (Clinical Professor of Urology, Chief) (Clinical Professor of Urology, Chief)

  4. Department of Urology, William Beaumont Hospital, Royal Oak, MI, 48073, USA

    Ananias C. Diokno M.D. (Clinical Professor of Urology, Chief) (Clinical Professor of Urology, Chief)

  5. Body MRI Section Department of Radiology, University of Miami School of Medicine, Miami, FL, 33101, USA

    Marco A. Amendola M.D. (Professor of Radiology and Radiation Oncology, Chief) (Professor of Radiology and Radiation Oncology, Chief)

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media New York

About this chapter

Cite this chapter

Diokno, A.C., Gonzalez, J.A. (1998). Malignancy of the Prostate Gland. In: Jafri, S.Z.H., Diokno, A.C., Amendola, M.A. (eds) Lower Genitourinary Radiology. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-1648-3_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-1648-3_11

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4612-7230-4

  • Online ISBN: 978-1-4612-1648-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation